Von Willebrand disease (hereditary or acquired)

This study tests an investigational drug called ALN-6400 in 24 women and teens with von Willebrand disease who have heavy menstrual bleeding. The goal is to see if the drug is safe and can reduce bleeding. Participants will receive multiple doses and be monitored for side effects…

This study tests a medicine called emicizumab to prevent bleeding episodes in people with Type 3 von Willebrand disease, a severe inherited bleeding disorder. About 75 participants, from infants to adults, will receive either emicizumab or continue their current treatment. The go…

This study tests a new medicine, HMB-002, in about 108 adults with von Willebrand disease (types 1 and 2). The goal is to check safety, how the drug moves in the body, and whether it helps control bleeding. It is the first time this drug is being tested in humans, starting with s…

This Phase 2 trial tests an injection called SR604 in 24 adults with von Willebrand disease, a bleeding disorder. The goal is to see if it safely reduces the number of bleeding episodes. Participants receive multiple doses, and researchers track bleeding rates and quality of life…

This study tests a drug called vonicog alfa to prevent bleeding in 24 children with severe von Willebrand disease, a condition that causes easy bruising and heavy bleeding. Participants receive the drug regularly for 12 months to see if it reduces bleeding episodes compared to th…

This study tests whether a step-by-step care plan (algorithm) can lower the chance of another serious stomach or nose bleed in people with von Willebrand disease. About 66 adults who have had such a bleed will be randomly assigned to either the new plan or standard care. The goal…

This study tests whether emicizumab (Hemlibra), a medicine given as a shot under the skin, can safely prevent bleeding in people with severe von Willebrand disease (VWD) or combined VWD/hemophilia A. About 40 participants of any age (including infants) will receive the drug and b…

This phase 3 study tests a drug called VGA039, given as a shot under the skin, to prevent bleeding in people with Von Willebrand disease. The trial will include 60 patients aged 12 to 75 who have frequent bleeding episodes. Researchers will track how well the drug reduces bleeds …

This study in Japan looks at how safe and effective Vonvendi (rVWF) is for children under 18 with Von Willebrand Disease, a bleeding disorder. About 13 kids will receive the drug as part of their normal care for bleeding episodes or before surgery. Researchers will monitor side e…

This early-stage trial tests a single dose of a lab-made clotting protein (recombinant von Willebrand factor) in 12 adult patients on ECMO who have major bleeding. The goal is to see if the drug is safe and how it behaves in the body. If successful, it may lead to a new way to co…

This study tests a drug called VONVENDI (recombinant von Willebrand factor) in 20 Chinese adults with von Willebrand disease, a bleeding disorder. The goal is to see if it is safe and helps control bleeding during surgery or dental procedures, sometimes combined with another drug…

This study looks at whether giving a medicine called Wilate to pregnant women with von Willebrand disease can prevent severe bleeding during and after childbirth. About 110 women will receive Wilate to keep their clotting factor levels high enough during delivery. The goal is to …

This study follows 300 teens and young adults (ages 10-24) with inherited bleeding disorders who choose either a levonorgestrel IUD or norethindrone acetate pills for heavy menstrual bleeding. Researchers will track bleeding patterns, satisfaction, and quality of life over six mo…

This early-phase study tests a new drug called BT200 in 4-6 adults with type 2B von Willebrand disease who have low platelets and a history of bleeding. The drug is designed to raise von Willebrand factor and platelet levels, which may lower the risk of bleeding. Participants rec…

This program provides continued compassionate access to recombinant von Willebrand factor (rVWF) for children and adults with severe von Willebrand disease who completed a prior study and are benefiting from treatment. Participants must have no comparable alternative therapy avai…

This study is testing a new device that mimics a blood vessel to evaluate how well a person's blood clots under realistic flow conditions. Researchers will compare results from healthy donors, patients with von Willebrand disease, and those on antiplatelet drugs. The goal is to s…

This study looks at whether giving iron through a vein (IV) can reduce bleeding symptoms in people with inherited bleeding disorders who also have low iron. About 40 participants will receive standard IV iron and be followed for 3 months to see if their bleeding, fatigue, and qua…

This study is collecting long-term safety and effectiveness data on treatments for various blood disorders, including hemophilia, sickle cell disease, and clotting disorders. It aims to enroll 3000 people of any age with these conditions. Researchers will monitor side effects, co…

This study is checking if a computer model can accurately predict why some people have a prolonged blood clotting time (APTT). The model uses data from routine blood tests to tell if the cause is harmless or a sign of a clotting disorder. Researchers will test it on 1,500 patient…

This study uses brain MRI scans to look for tiny old bleeds (microbleeds) in 200 adults with severe hemophilia or von Willebrand disease. Researchers want to see how common these microbleeds are and whether they are linked to memory or thinking difficulties. Participants will als…

This study is testing a new, non-invasive method to predict bleeding risk in people with von Willebrand disease and other inherited bleeding disorders. Researchers will use a special microscope to look at tiny blood vessels under the tongue. The goal is to see if the density of t…

This study is for people aged 16 to 70 with von Willebrand disease (VWD), a bleeding disorder. Researchers will collect information on bleeding events, treatments, and quality of life over time. The goal is to understand the real-world impact of VWD and use this data as a baselin…

This study creates a web-based registry for people with severe von Willebrand disease (sVWD), a rare bleeding disorder. Researchers will collect information from up to 400 participants about their medical history, symptoms, and lab results. The goal is to build a detailed databas…

This study is a large registry that collects health information from up to 200,000 people with blood disorders such as hemophilia, thrombosis, and sickle cell disease. Participants are seen at Hemophilia Treatment Centers across the U.S. The goal is to gather real-world data to h…

This study looks at how well hip, knee, shoulder, and other joint replacement surgeries work in adults with inherited bleeding disorders like hemophilia. Researchers will collect information from medical records and follow patients over time to understand risks, complications, an…

This observational study aims to understand how endothelial colony-forming cells (ECFCs) behave in people with von Willebrand disease (VWD) and acquired von Willebrand syndrome (AVWS) compared to healthy individuals. Researchers will collect blood samples from 48 participants to …

This study looks at how blood cells interact and what goes wrong in inherited bleeding disorders like Glanzmann thrombasthenia. Researchers will analyze blood samples from up to 60 healthy volunteers and patients to find genetic defects. The goal is to better understand these con…